Celldex Therapeutics Inc CLDX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CLDX is a good fit for your portfolio.
News
-
Celldex Therapeutics to Present at Jefferies Healthcare Conference
-
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
-
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
-
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
-
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
-
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
-
Celldex Therapeutics shares surge as lead asset shows promise in two skin conditions
Trading Information
- Previous Close Price
- $33.02
- Day Range
- $32.79–34.62
- 52-Week Range
- $22.10–52.98
- Bid/Ask
- $34.37 / $34.43
- Market Cap
- $2.27 Bil
- Volume/Avg
- 251,785 / 737,093
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 279.23
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 160
- Website
- https://www.celldex.com
Comparables
Valuation
|
Metric
|
CLDX
|
ITOS
|
ANAB
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.59 | 1.15 | 14.25 |
Price/Sales | 279.23 | — | 28.91 |
Price/Cash Flow | — | — | — |
Price/Earnings
CLDX
ITOS
ANAB
Financial Strength
|
Metric
|
CLDX
|
ITOS
|
ANAB
|
|---|---|---|---|
Quick Ratio | 31.44 | 12.80 | 11.20 |
Current Ratio | 31.77 | 13.51 | 11.53 |
Interest Coverage | — | — | −8.08 |
Quick Ratio
CLDX
ITOS
ANAB
Profitability
|
Metric
|
CLDX
|
ITOS
|
ANAB
|
|---|---|---|---|
Return on Assets (Normalized) | −23.59% | −16.56% | −25.16% |
Return on Equity (Normalized) | −25.21% | −18.86% | −101.95% |
Return on Invested Capital (Normalized) | −25.04% | −22.78% | −87.63% |
Return on Assets
CLDX
ITOS
ANAB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lvfyrhmjqn | Hmqf | $608.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rytvjpqzx | Hzmjxpb | $124.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hywlqbrv | Xlmrfw | $110.8 Bil | |
MRNA
| Moderna Inc | Lglrnytk | Pwth | $59.3 Bil | |
BNTX
| BioNTech SE ADR | Rlzprwsb | Ffzs | $24.7 Bil | |
ARGX
| argenx SE ADR | Hkxwwctn | Qtqs | $22.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ppvyhblt | Zndntxg | $19.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hrwjkyx | Smnszq | $15.1 Bil | |
INCY
| Incyte Corp | Fdsmgdvqm | Brfwpk | $13.3 Bil | |
TECH
| Bio-Techne Corp | Nbgvfbxvnh | Vwlwfwg | $12.5 Bil |